{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:19:06Z","timestamp":1785860346066,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012515","name":"Cyrus Tang Foundation","doi-asserted-by":"publisher","award":["ZSBK0070"],"award-info":[{"award-number":["ZSBK0070"]}],"id":[{"id":"10.13039\/100012515","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Fudan University Education Development Foundation","award":["ZSBK0046"],"award-info":[{"award-number":["ZSBK0046"]}]},{"name":"Shanghai Municipal Committee of Science and Technology","award":["21Y31900302"],"award-info":[{"award-number":["21Y31900302"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40801-024-00468-5","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T06:46:12Z","timestamp":1734677172000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed\/Refractory High-Risk Neuroblastoma at the Children\u2019s Hospital of Fudan University"],"prefix":"10.1007","volume":"12","author":[{"given":"Xiaowen","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dufei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuiran","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"4","key":"468_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/14737140.2017.1285230","volume":"17","author":"SB Whittle","year":"2017","unstructured":"Whittle SB, Smith V, Doherty E, et al. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369\u201386.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"24","key":"468_CR2","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/cncr.30934","volume":"123","author":"WB London","year":"2017","unstructured":"London WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials. Cancer. 2017;123(24):4914\u201323.","journal-title":"Cancer"},{"issue":"16","key":"468_CR3","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.28748","volume":"120","author":"MA Smith","year":"2014","unstructured":"Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality. Cancer. 2014;120(16):2497\u2013506.","journal-title":"Cancer"},{"key":"468_CR4","unstructured":"PDQ\u00ae Pediatric Treatment Editorial Board. Neuroblastoma treatment (PDQ\u00ae): health professional version. National Cancer Institute. Available from: https:\/\/www.cancer.gov\/types\/neuroblastoma\/hp\/neuroblastoma-treatment-pdq. Accessed 1 Jul 2023."},{"issue":"3","key":"468_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ped4.12214","volume":"4","author":"Y Su","year":"2020","unstructured":"Su Y, Qin H, Chen C, et al. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatr Investig. 2020;4(3):157\u201367.","journal-title":"Pediatr Investig."},{"issue":"4","key":"468_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4161\/onci.19864","volume":"1","author":"NK Cheung","year":"2012","unstructured":"Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1(4):477\u201386.","journal-title":"Oncoimmunology."},{"key":"468_CR7","unstructured":"Danyelza\u00ae (naxitamab) prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761171lbl.pdf. [Accessed Jul 2023]."},{"issue":"11","key":"468_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1358331","volume":"6","author":"IY Cheung","year":"2017","unstructured":"Cheung IY, Kushner BH, Modak S, et al. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology. 2017;6(11): e1358331.","journal-title":"Oncoimmunology."},{"issue":"12","key":"468_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","volume":"4","author":"BH Kushner","year":"2018","unstructured":"Kushner BH, Cheung IY, Modak S, et al. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial. JAMA Oncol. 2018;4(12):1729\u201335.","journal-title":"JAMA Oncol"},{"issue":"1","key":"468_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1627","volume":"6","author":"J Mora","year":"2023","unstructured":"Mora J, Chan GC, Morgenstern DA, et al. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and\/or relapsed high-risk neuroblastoma: management of adverse events. Cancer Rep (Hoboken). 2023;6(1): e1627.","journal-title":"Cancer Rep (Hoboken)."},{"issue":"6","key":"468_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40272-021-00469-9","volume":"23","author":"G Barone","year":"2021","unstructured":"Barone G, Barry A, Bautista F, et al. Managing adverse events associated with dinutuximab beta treatment in patients with high-risk neuroblastoma: practical guidance. Paediatr Drugs. 2021;23(6):537\u201348.","journal-title":"Paediatr Drugs"},{"key":"468_CR12","unstructured":"Mora J, Bear MK, Chang GC, et al. Naxitamab pivotal clinical trial: interim analysis report of subgroup outcomes in relapsed or refractory high-risk neuroblastoma [abstract #2619]. In: Oral presentation at SIOP; September 2022; Barcelona."},{"issue":"22","key":"468_CR13","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"468_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30217","volume":"70","author":"K Nysom","year":"2023","unstructured":"Nysom K, Morad AG, Rafael MS, et al. Pain mitigation and management strategies for anti-GD2 infusions: an expert consensus. Pediatr Blood Cancer. 2023;70(5): e30217.","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl 16","key":"468_CR15","doi-asserted-by":"publisher","first-page":"10032","DOI":"10.1200\/JCO.2024.42.16_suppl.10032","volume":"42","author":"J Mora","year":"2024","unstructured":"Mora J, Chan GC, Morgenstern DA, et al. Naxitamab-related adverse events within and across treatment cycles in patients with relapsed\/refractory (R\/R) high-risk neuroblastoma [abstract]. J Clin Oncol. 2024;42(Suppl 16):10032.","journal-title":"J Clin Oncol"},{"issue":"3","key":"468_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7045","volume":"13","author":"EM Trovillion","year":"2024","unstructured":"Trovillion EM, Michael M, Jordan CC, et al. Guidelines for outpatient administration of naxitamab: experience from Atrium Health Levine Children\u2019s Hospital. Cancer Med. 2024;13(3): e7045.","journal-title":"Cancer Med"},{"issue":"2","key":"468_CR17","doi-asserted-by":"publisher","first-page":"100462","DOI":"10.1016\/j.esmoop.2022.100462","volume":"7","author":"A Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda A, Gorostegui M, Miralles SL, et al. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de D\u00e9u in Barcelona, Spain. ESMO Open. 2022;7(2):100462. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100462. (Epub 2022 Apr 6. Erratum in: ESMO Open. 2022 May 26;7(3):100504).","journal-title":"ESMO Open."},{"issue":"1","key":"468_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40272-022-00544-9","volume":"25","author":"J Cabral","year":"2023","unstructured":"Cabral J, Fernandez EI, Toy B, Secola R. Multidisciplinary clinical care in the management of patients receiving anti-GD2 immunotherapy for high-risk neuroblastoma. Paediatr Drugs. 2023;25(1):13\u201325.","journal-title":"Paediatr Drugs"},{"issue":"44","key":"468_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123417119","volume":"119","author":"PC Chen","year":"2022","unstructured":"Chen PC, Zhang J, Thayer JF, Mednick SC. Understanding the roles of central and autonomic activity during sleep in the improvement of working memory and episodic memory. Proc Natl Acad Sci USA. 2022;119(44): e2123417119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"468_CR20","unstructured":"Unituxin\u00ae (dinutuximab) prescribing information. Available from: https:\/\/www.unituxin.com\/hcp\/side-effects-safety\/. Accessed 1 Feb 2023."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00468-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T18:28:18Z","timestamp":1739644098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00468-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00468-5","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"12 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding was received from the National Key R&D Program of China (2023YFC2706301), the National Key R&D Program of China (2022YFC2705003), the National Natural Science Foundation of China (82141125), and the Shanghai Hospital Development Center (SHDC12023109).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James Eldridge reports employment with Y-mAbs Therapeutics Inc. Xiaowen Qian, Dufei Zhang, Kai Li, Weiming Chen, Peijun Zhuang, Hongsheng Wang, Zhixian Lei, Yan Li, Kuiran Dong, and Xiaowen Zhai have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The Institutional Review Board of the Hainan Women and Children\u2019s Medical Center of Fudan University approved the study on 2021\/07\/02 with ethics approval number HNWCMC \u4f26\u5ba1 2021\u5e74\u7b2c[84]\u53f7.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all patients before naxitamab treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"XQ: contributions to the conception or design of the work; drafting the work. DZ: contribution to acquisition of data for the work; reviewing it critically for important intellectual content. KL: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. WC: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. PZ: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. HW: contributions to interpretation of data for the work; reviewing it critically for important intellectual content. ZL: contribution to acquisition of data for the work; contributions to interpretation of data for the work. YL: contribution to acquisition of data for the work. JE: contribution to analysis of data for the work. KD: final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. XZ: final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All the authors have read and approved the manuscript of the last version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}